Over the past 20 years, Nazneen Rahman, professor and Head of the Division of Genetics and Epidemiology at the Institute of Cancer Research, has identified a steady stream of genes that influence the risk of breast, ovarian, and childhood cancers. But her latest accomplishment, and one of her proudest, is very different. Rahman has created a shortcut in the British healthcare system that will give women with ovarian cancer access to a critical genetic test. The new pathway is cost-efficient, saving time and money as well as lives.
The Clinical Pathway mentioned:
A discrete event simulation to evaluate the cost effectiveness of germline BRCA1 and BRCA2 testing in UK women with ovarian cancer
Anthony Eccleston, Anthony Bentley, Matthew Dyer, Ann Strydom, Wim Vereecken, Angela George, Nazneen Rahman
bioRxiv 060418; doi: http://dx.doi.org/10.1101/060418
Read more here.
No comments:
Post a Comment